CRISPR Therapeutics AG Among Most Shorted Mid-Cap Stocks on Robust Gene Editing Pipeline

CRISPR Therapeutics AG (CRSP) is listed as one of the most shorted mid-cap stocks recommended for purchase, owing to its robust gene editing pipeline. The company's strong research and development efforts are seen as a key growth driver.